San Francisco And Suzhou News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from San francisco and suzhou. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In San Francisco And Suzhou Today - Breaking & Trending Today

Innovent and IASO Bio Present Updated Data of BCMA CAR-T Cell Therapy (Equecabtagene Autoleucel) at EHA 2022

SAN FRANCISCO and SUZHOU, China, June 13, 2022 /PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, today jointly announced that the updated data from phase 1/2 study of Equecabtagene Autoleucel (Innovent R&D code: IBI326, IASO Bio R&D code: CT103A), a fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma (R/R MM), was presented in the form of an oral presentation at the 27th European Hematology Association (EHA) Annual Meeting in Vienna on June 9-12, 2022 ....

United States , Hong Kong , Innovent Biologics , Equecabtagene Autoleucel Chi , Adimab Incyte , Equecabtagene Autoleucel , Chunrui Li , Eli Lilly , Equecabtagene Autoleucel Innovent , European Hematology Association , Md Anderson Cancer Center , China National Medical Products Administration , Huazhong University Of Science Technology , Department Of Hematology , Innovent Or Company , Incyte Corporation , Huazhong University Of Science , Prnewswire Innovent Biologics Inc , Drug Administration , Tongji Medical College , Tongji Hospital Of Medical College , Office Of Orphan Products Development , Innovent Biologics Inc , Annual Meeting , Updated Phase , Refractory Multiple ,

Innovent Announces Phase 2 study of MazdutideIBI362 in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints

SAN FRANCISCO and SUZHOU, China, June 8, 2022 /PRNewswire/ Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announces that the primary and all key secondary endpoints were met in a randomized, double-blind, placebo-controlled phase 2 study of mazdutide (R&D code: IBI362), a glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR) dual agonist, in Chinese participants with overweight or obesity. This study (ClinicalTrials.gov, NCT04904913) was designed to evaluate the efficacy and safety of mazdutide in Chinese participants with overweight or obesity. A total of 248 subjects were randomized to receive 1.5-3.0 mg, 1.5-3.0-4.5 mg, or 2.0-4.0-6.0 mg of mazdutide or placebo subcutaneously and once-weekly for 24 weeks. The primary endpoint was the percentage change from base ....

United States , Hong Kong , Innovent Biologics , Adimab Incyte , Eli Lilly , Linong Ji , Clinical Development Of Innovent , Company Lilly , Md Anderson Cancer Center , University People Hospital , Incyte Corporation , Innovent Biologics Inc , Peking University People , Lei Qian , Vice President , Clinical Development , Main Board , Stock Exchange , Hong Kong Limited , Cancer Center , Mainland China , San Francisco And Suzhou , June 8 , 022 Prnewswire Innovent Biologics , Nc Innovent Hkex 01801 , A World Class Biopharmaceutical Company That Develops ,

Innovent Releases Results of High-dose Cohorts in Phase 1 Clinical Study of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity at ENDO 2022

SAN FRANCISCO and SUZHOU, China, June 13, 2022 /PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the results of high-dose cohorts in a phase 1 clinical trial of mazdutide (IBI362), a glucagon-like petide-1 (GLP-1) and glucagon receptor dual agonist, in Chinese adults with overweight or obesity are presented as an on-demand poster (ODP014) at ENDO 2022. This randomized, double-blind, placebo-controlled multiple-ascending-dose study (ClinicalTrials.gov, NCT04440345) evaluated the safety, tolerability and PK/PD characteristics of mazdutide in Chinese participants with overweight or obesity. Twelve participants in each of the five cohorts were randomized 2:1 to receive subcutaneous 1.0-2.0-3.0 mg (cohort 1), 1.5-3.0-4.5 mg (cohort 2), 2.0-4.0-6.0 ....

United States , Hong Kong , Innovent Biologics , Adimab Incyte , Eli Lilly , Linong Ji , Clinical Development Of Innovent , Company Lilly , Prnewswire Innovent Biologics Inc , Md Anderson Cancer Center , University People Hospital , Innovent Or Company , Incyte Corporation , Innovent Biologics Inc , Principal Investigator , Peking University People , Lei Qian , Vice President , Clinical Development , Main Board , Stock Exchange , Hong Kong Limited , Cancer Center , Mainland China , San Francisco And Suzhou , June 13 ,

Innovent and Etana Jointly Announce the Approval of Bevagen (Bevacizumab Biosimilar) by the Indonesian Food and Drugs Authority (BPOM)

SAN FRANCISCO and SUZHOU, China, June 14, 2022 /PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and PT Etana Biotechnologies Indonesia ("Etana"), today jointly announced that the Indonesian Food and Drugs Authority (BPOM) has approved Bevagen (bevacizumab biosimilar), a recombinant humanized anti-VEGF monoclonal antibody drug, for five indications including metastatic colorectal cancer (mCRC), locally recurrent or metastatic triple negative breast cancer (mTNBC), advanced, metastatic, or recurrent non-small cell lung cancer(NSCLC), epithelial ovarian, fallopian tube, and primary peritoneal cancer (OC), and cervical cancer(CC). Etana will commercialize Bevagen in Indonesia under the current licensing agreement with Innovent. Bevagen will potentially ....

United States , Hong Kong , Innovent Biologics , Bevagen Bevacizumab Biosimilar , Adimab Incyte , Nathan Tirtana , Michael Yu , Eli Lilly , Indonesian Ulema Council , National Medical Product Administration , Drugs Authority , Md Anderson Cancer Center , Innovent Or Company , Incyte Corporation , Innovent Biologics Inc , Biotechnologies Indonesia , Indonesian Food , President Director , Mainland China , Bevacizumab Biosimilar , Main Board , Stock Exchange , Hong Kong Limited , Cancer Center , Southeast Asian , San Francisco And Suzhou ,